Avenna Admin

Glycans Hit the Sweet Spot in Diagnostics

Glycans Hit the Sweet Spot in Diagnostics

Glycans Hit the Sweet Spot in Diagnostics January 2022  Our CEO Nina Skorytchenko and other innovators in this field  discussing about how Glycans can be used for early diagnostics and disease prevention. Click here to read the article.

Targeting inflammaging through glycomics

Targeting inflammaging through glycomics

Targeting inflammaging through glycomics     Longevity technology is Daily news and insights on the fast-growth longevity market, here are articles about Targeting inflammaging through glycomics. Click here to read the article.

Introduction to Avenna

Introduction to Avenna        In this video, we explain how our in-vitro diagnostic platform technology- GlyHealth can enhance healthcare for chronic inflammatory diseases. We explain the benefits of our biomarkers for different members of healthcare ecosystem, including clinicians and drug development companies.   BACK TO MEDIA GALLERY

ImmunofrailityTest- Instruction video

Immunofraility Test. Instruction video        In this video, we explain Avenna’s core technology, GlyHealth. We explain the current four variants in our development pipeline including, GlyHealth-Index, IBD, SCI, and COVID-19, and expand on GlyHealth-Index and IBD. This video also compares conventional vs glycomic biomarkers for early detection and treatment personalisation of inflammatory disease.

Avenna Women in Innovation

Avenna Women in Innovation video 2021        In this video, we explain Avenna’s core technology, GlyHealth. We explain the current four variants in our development pipeline including, GlyHealth-Index, IBD, SCI, and COVID-19, and expand on GlyHealth-Index and IBD. This video also compares conventional vs glycomic biomarkers for early detection and treatment personalisation of …

Avenna Women in Innovation Read More »

Avenna at SEHTA Conference

Avenna at SEHTA Conference              In this video, we explain Avenna’s core technology, GlyHealth. We explain the current four variants in our development pipeline including, GlyHealth-Index, IBD, SCI, and COVID-19, and expand on GlyHealth-Index and IBD. This video also compares conventional vs glycomic biomarkers for early detection and treatment personalisation …

Avenna at SEHTA Conference Read More »

https://www.linkedin.com/posts/avenna-ltd_glycans-are-crucial-in-covid-19-infection-activity-6785481637766414336-4xrj

WuXi HealthCare forum presentation

WuXi HealthCare forum presentation In this video, we explain Avenna’s core technology, GlyHealth. We explain the current four variants in our development pipeline including, GlyHealth-Index, IBD, SCI, and COVID-19, and expand on GlyHealth-Index and IBD. This video also compares conventional vs glycomic biomarkers for early detection and treatment personalisation of inflammatory disease. Click here to see …

WuXi HealthCare forum presentation Read More »

Avenna at NOAH Conference

Avenna at NOAH Conference 2019        This is a recording of our presentation at this renown tech conference. Our CEO discusses the burden of chronic inflammatory diseases (CIDs) and limitations in CIDs diagnostic procedures. Additionally, this presentation explains how Avenna medical technology can reliably detect and predict future CIDs using molecular signals from …

Avenna at NOAH Conference Read More »